Progyny Inc
PGNY
View Detailed Chart
22.420USD
-0.090-0.40%
Market hours （ET）Quotes delayed by 15 min
1.93BMarket Cap
36.26P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.40%
5 Days
-0.58%
1 Month
-0.58%
6 Months
+10.12%
Year to Date
+29.97%
1 Year
-7.16%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Buy
Current Rating
28.714
Target Price
+27.56%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.33% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 78.98.
Undervalued
The company’s latest PE is 36.38, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.53M shares, decreasing 22.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.85M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
Ticker SymbolPGNY
CompanyProgyny Inc
CEOMr. Peter (Pete) Anevski
Websitehttps://www.progyny.com/
